RBM39 Protein (CAPER)
Overview
RBM39, also known as CAPER (Coactivator of AP-1 and estrogen receptor), is an RNA-binding protein belonging to the SR protein (serine/arginine-rich protein) family. This multifunctional nuclear protein is encoded by the RBM39 gene located on chromosome 20q11.23. RBM39 was initially characterized as a coactivator for nuclear hormone receptors but has emerged as a critical regulator of pre-mRNA splicing, transcriptional regulation, and cellular stress responses. The protein contains characteristic RNA recognition motifs (RRMs) and an RS domain rich in serine and arginine residues, hallmark features of SR proteins that facilitate both RNA binding and protein-protein interactions. RBM39's role has expanded significantly beyond its original characterization, with recent research implicating its dysfunction in neurodegenerative diseases, particularly through its involvement in alternative splicing of disease-associated genes.
Function and Biology
RBM39 operates as a splicing regulatory protein with dual functionality in transcriptional and post-transcriptional gene regulation. The protein contains two N-terminal RNA recognition motifs that enable specific binding to RNA targets, typically within defined sequence elements in pre-mRNA substrates. Its RS domain acts as a protein-interaction hub, facilitating recruitment to the spliceosome and interactions with other splicing factors and coactivator complexes.
...RBM39 Protein (CAPER)
Overview
RBM39, also known as CAPER (Coactivator of AP-1 and estrogen receptor), is an RNA-binding protein belonging to the SR protein (serine/arginine-rich protein) family. This multifunctional nuclear protein is encoded by the RBM39 gene located on chromosome 20q11.23. RBM39 was initially characterized as a coactivator for nuclear hormone receptors but has emerged as a critical regulator of pre-mRNA splicing, transcriptional regulation, and cellular stress responses. The protein contains characteristic RNA recognition motifs (RRMs) and an RS domain rich in serine and arginine residues, hallmark features of SR proteins that facilitate both RNA binding and protein-protein interactions. RBM39's role has expanded significantly beyond its original characterization, with recent research implicating its dysfunction in neurodegenerative diseases, particularly through its involvement in alternative splicing of disease-associated genes.
Function and Biology
RBM39 operates as a splicing regulatory protein with dual functionality in transcriptional and post-transcriptional gene regulation. The protein contains two N-terminal RNA recognition motifs that enable specific binding to RNA targets, typically within defined sequence elements in pre-mRNA substrates. Its RS domain acts as a protein-interaction hub, facilitating recruitment to the spliceosome and interactions with other splicing factors and coactivator complexes.
As a nuclear protein, RBM39 localizes predominantly to nuclear speckles and the nucleoplasm, compartments where active splicing and transcriptional regulation occur. The protein functions as a bridge between transcriptional machinery and splicing apparatus, coordinating the coupling of transcription with RNA processing. RBM39 has been shown to interact with the estrogen receptor and other nuclear hormone receptors, enhancing their transcriptional activity. Additionally, RBM39 participates in the regulated splicing of multiple pre-mRNA targets, influencing the production of functionally distinct protein isoforms.
Role in Neurodegeneration
RBM39's involvement in neurodegeneration has become increasingly apparent through multiple research avenues. The protein plays a crucial role in regulating the alternative splicing of genes implicated in neurodegenerative pathways, including those involved in neuroinflammation, proteostasis, and neuronal survival. Dysregulation of RBM39 expression or function has been associated with altered splicing patterns of disease-relevant transcripts in both Alzheimer's disease and Parkinson's disease contexts.
Research has demonstrated that RBM39 participates in the splicing regulation of genes encoding proteins involved in the unfolded protein response (UPR), a critical cellular mechanism for managing proteotoxic stress. Impaired RBM39 function may compromise the cell's ability to adequately respond to protein misfolding and aggregation—central pathological features of neurodegenerative diseases. Additionally, RBM39 influences splicing of genes encoding components of the ubiquitin-proteasome system and autophagy machinery, both essential for clearing misfolded proteins that accumulate during neurodegeneration.
Molecular Mechanisms
RBM39 exerts its effects through several integrated molecular mechanisms. The protein recognizes specific RNA sequences and structural elements through its RRM domains, typically binding to pyrimidine-rich elements (GCGCCCCN repeats) within target pre-mRNAs. Upon binding, RBM39 recruits additional splicing factors and promotes the assembly or remodeling of the spliceosome, leading to either exon inclusion or exclusion depending on the specific target and cellular context.
The RS domain undergoes dynamic phosphorylation, particularly by SRPK1 (SR protein kinase 1) and other kinases, modulating RBM39's RNA-binding affinity and subcellular localization. This post-translational modification is critical for regulating RBM39's activity in response to cellular signals and stress conditions. RBM39 also exhibits stress-responsive behavior, with its nuclear accumulation and splicing activity altered during heat stress, oxidative stress, and endoplasmic reticulum stress—all conditions relevant to neurodegeneration.
Clinical and Research Significance
RBM39 represents an emerging therapeutic target for neurodegenerative disease intervention. Studies exploring RBM39 expression levels in patient-derived neural tissues and postmortem brain samples from neurodegenerative disease patients have revealed disease-associated expression changes. Modulating RBM39 function could potentially normalize the splicing of neuroprotective genes or suppress the production of neurotoxic protein isoforms.
The protein has gained attention in cancer research as well, with certain compounds targeting RBM39 function through mechanisms including proteasomal degradation. These discoveries provide a foundation for developing selective RBM39 modulators that could potentially benefit neurodegenerative disease patients while minimizing off-target effects.
RBM39 functionally and structurally relates to other SR proteins including SRSF1, SRSF3, and SRSF7, which coordinate splicing regulation. Related pathways involve the unfolded protein response, ubiquitin-proteasome system, and autophagy. Associated diseases include Alzheimer's disease, Parkinson's